Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drug
VEPPANU won FDA approval and was licensed to Rigel Pharmaceuticals, while Arvinas outlined data timelines for three Phase 1 programs and cash runway into second-half 2028.
SEC filing